Jeremy Grantham's GILD Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 112,198 shares of Gilead Sciences, Inc. (GILD) worth $13.77 M, representing 0.04% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in GILD, representing a significant commitment to this investment thesis. Largest addition occurred in Q3 2016, adding 742,616 shares. Largest reduction occurred in Q1 2014, reducing 2.87 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Gilead Sciences (GILD) Holding Value Over Time
Track share changes against reported price movement
Quarterly Gilead Sciences (GILD) Trades by Jeremy Grantham
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +20,225 | Add 21.99% | 112,198 | $122.74 |
| Q3 2025 | +68,006 | Add 283.75% | 91,973 | $111.00 |
| Q2 2025 | +13,597 | Add 131.12% | 23,967 | $110.87 |
| Q1 2025 | -2,698 | Reduce 20.65% | 10,370 | $112.05 |
| Q4 2024 | -47,570 | Reduce 78.45% | 13,068 | $92.37 |
| Q3 2024 | -172,623 | Reduce 74.00% | 60,638 | $83.84 |
| Q2 2024 | +233,261 | New Buy | 233,261 | $68.61 |
| Q1 2024 | -286,270 | Sold Out | 0 | $0.00 |
| Q4 2023 | +37,031 | Add 14.86% | 286,270 | $81.01 |
| Q3 2023 | -20,565 | Reduce 7.62% | 249,239 | $74.94 |
| Q2 2023 | -19,880 | Reduce 6.86% | 269,804 | $77.07 |
| Q1 2023 | +44,704 | Add 18.25% | 289,684 | $82.97 |
| Q4 2022 | -299,016 | Reduce 54.97% | 244,980 | $85.85 |
| Q3 2022 | -35,900 | Reduce 6.19% | 543,996 | $61.69 |
| Q2 2022 | +91,200 | Add 18.66% | 579,896 | $61.81 |
| Q1 2022 | +74,696 | Add 18.04% | 488,696 | $59.45 |
| Q4 2021 | -1,900 | Reduce 0.46% | 414,000 | $72.61 |
| Q3 2021 | +43,400 | Add 11.65% | 415,900 | $69.85 |
| Q2 2021 | +88,600 | Add 31.21% | 372,500 | $68.86 |
| Q1 2021 | +108,870 | Add 62.20% | 283,900 | $64.63 |
| Q4 2020 | +93,700 | Add 115.21% | 175,030 | $58.26 |
| Q3 2020 | +100 | Add 0.12% | 81,330 | $63.19 |
| Q2 2020 | +31,461 | Add 63.21% | 81,230 | $76.94 |
| Q1 2020 | -122,655 | Reduce 71.14% | 49,769 | $74.77 |
| Q4 2019 | -42,076 | Reduce 19.62% | 172,424 | $64.98 |
| Q3 2019 | -38,300 | Reduce 15.15% | 214,500 | $63.38 |
| Q2 2019 | +6,900 | Add 2.81% | 252,800 | $67.56 |
| Q1 2019 | +245,900 | New Buy | 245,900 | $65.01 |
| Q3 2018 | -9,600 | Sold Out | 0 | $0.00 |
| Q2 2018 | +300 | Add 3.23% | 9,600 | $70.83 |
| Q4 2017 | +9,300 | New Buy | 9,300 | $71.61 |
| Q3 2017 | -6,800 | Sold Out | 0 | $0.00 |
| Q2 2017 | -30,600 | Reduce 81.82% | 6,800 | $70.74 |
| Q1 2017 | -837,284 | Reduce 95.72% | 37,400 | $67.91 |
| Q4 2016 | -291,032 | Reduce 24.97% | 874,684 | $71.61 |
| Q3 2016 | +742,616 | Add 175.52% | 1.17 M | $79.12 |
| Q2 2016 | +325,500 | Add 333.50% | 423,100 | $83.42 |
| Q1 2016 | +94,000 | Add 2611.11% | 97,600 | $91.86 |
| Q2 2015 | -1,000 | Reduce 21.74% | 3,600 | $116.94 |
| Q4 2014 | -2,100 | Reduce 31.34% | 4,600 | $94.35 |
| Q3 2014 | -3,900 | Reduce 36.79% | 6,700 | $106.42 |
| Q2 2014 | -506,346 | Reduce 97.95% | 10,600 | $82.92 |
| Q1 2014 | -2.87 M | Reduce 84.74% | 516,946 | $70.86 |
| Q4 2013 | +464,338 | Add 15.89% | 3.39 M | $75.15 |
| Q3 2013 | +391,794 | Add 15.48% | 2.92 M | $62.84 |
| Q2 2013 | +2.53 M | Add 0.00% | 2.53 M | $51.21 |
Jeremy Grantham's Gilead Sciences Investment FAQs
Jeremy Grantham first purchased Gilead Sciences, Inc. (GILD) in Q2 2013, acquiring 2,530,605 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Gilead Sciences, Inc. (GILD) for 50 quarters since Q2 2013.
Jeremy Grantham's largest addition to Gilead Sciences, Inc. (GILD) was in Q2 2013, adding 2,530,605 shares worth $129.59 M.
According to the latest 13F filing for Q4 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 112,198 shares of Gilead Sciences, Inc. (GILD), valued at approximately $13.77 M.
As of the Q4 2025 filing, Gilead Sciences, Inc. (GILD) represents approximately 0.04% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings.
Jeremy Grantham's peak holding in Gilead Sciences, Inc. (GILD) was 3,386,737 shares, as reported at the end of Q4 2013.